Alloy is Building the World's First Fully Integrated Product Development
Organization - Read the full article
How AI is reshaping antibody discovery and optimization workflows
In silico antibody discovery and optimization: How computational tools are reshaping the workflow AI-enabled and ML-powered methods are enabling faster identification and engineering of high-quality therapeutic antibody leads The field of antibody discovery is experiencing a transformative shift through the integration of cutting-edge artificial intelligence (AI) and machine learning (ML) technologies. Traditional methods of antibody […]
Discovery of highly-specific TCR mimic antibodies to WT1
Navigating high homology: Discovery of TCR mimic antibodies with greater specificity to Wilms tumor 1 antigen The development of TCR mimic (TCRm) antibodies (or TCR-like antibodies) offers a promising new approach for cancer immunotherapy but identifying TCRm antibody candidates with optimal specificity and low off-target effects can be challenging. Here, we look at an antibody […]
Daedamab High Velocity Antibody Discovery
Access the webinar recording Thanks for your interest in our recent Daedamab webinar recording. Please fill out the form, and we will send you a link to the webinar with a passcode shortly. Our approach generates a diverse set of antibody candidates in as little as 2-3 months Daedamab offers a novel, fast, powerful sequence-first […]
Keyway TCRm Discovery Webinar
Access the webinar recording Thanks for your interest in our recent Keyway TCR mimic Discovery webinar, Increasing Target Specificity and Tackling Intracellular Targets for TCRm Therapeutics Development with Keyway’s TCRm Discovery Offering. In it, the team at the helm of our TCR mimic discovery campaigns shared: 1. An overview of common challenges to intracellular protein-targeting drug discovery […]
Discovering Antibodies in Months
Access the webinar recording Thanks for your interest in our recent antibody discovery webinar, Discovering Antibodies in Months: New Advances in HT-SPR, Single-Cell BCR-Seq and RNA-Seq. Alloy Head of Global Bioanalytics Dr. Lucy Liu presented on our workflow that improve the speed and quality of the antibody discovery process. Please fill out your contact information, and […]
Approaches to Binder Recovery Following Immunization Campaigns in Mouse Models
Harnessing the Potential of Human Lambda Light Chains in Antibody Discovery Campaigns
Targeting GPCRs With DeepImmune™
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation. BOSTON, Mass. – September 20, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the formation of its scientific advisory board (SAB) that includes a group of renowned experts in fields spanning immunology, protein engineering, T cell receptor (TCR) modalities, and […]
High Efficiency CAR Discovery Screening
Chimeric antigen receptor cell therapy (CAR-T, CAR-NK, etc.) is a promising therapeutic modality, but functional screening is a bottleneck for traditional two-step CAR-T discovery process of antibody binder discovery and CAR-T functional engineering. In this webinar, scientists at Alloy showcase their unique CAR discovery workflow that incorporates human antibody identification and characterization, mRNA-based CAR construct […]